FDA-Approved Nasal Spray For Depression Is 1st Of Its Kind

FDA approves Johnson & Johnson’s ketamine-derived nasal spray for depression as stand-alone treatment
The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult population.
J&J's ketamine-derived nasal spray approved by FDA to treat depression
Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those who had an inadequate response to oral antidepressants.
US FDA Approves First Of Its Kind Ketamine-Based Nasal Spray To Treat Depression: Know All About This Drug
The US FDA has approved the first of its kind ketamine-based nasal spray which is supposed to act as a standalone therapy for treatment-resistant depression.
Johnson & Johnson ketamine-derived nasal spray gets FDA approval for depression, but JNJ stock dips on earnings
Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven’t responded to oral antidepressants. On Tuesday, the Food and Drug Administration (FDA) approved Johnson & Johnson’s nasal spray,
FDA-approved nasal spray for severe depression can lead to remission
The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in people who have not responded to at least two oral antidepressants.
FDA approves first-of-its-kind nasal spray for severe depression
Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD, and similar psychiatric conditions.
Can a Nasal Spray Really Help Treat Depression? Here's What to Know About Spravato
Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.
Ketamine-Derived Nasal Spray Approved as Standalone Treatment for Tough Depression Cases
An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a standalone therapy for cases of depression that haven’t responded to other options.
Johnson & Johnson's Spravato nasal spray okayed as stand-alone treatment for depression
Spravato, okayed for stand-alone use among adults, is the first such therapy for major depressive disorder (MDD) that is difficult to treat.
Research indicates recreational ketamine use is on the rise
Respondents who said they used other drugs recreationally were also likelier to say they used ketamine during the past year ...
US Weekly on MSN10d
What Celebrities and Doctors Have Said About Ketamine Use: Chrissy Teigen, Matthew Perry, More
Celebrities like Chrissy Teigen and Matthew Perry have been open about using ketamine for their mental health – here's what ...
Does Medicare cover ketamine infusions for mental health conditions?
Because it is still awaiting approval, Medicare does not typically cover the use of ketamine infusion for treating mental ...
Ketamine-assisted therapy clinic opens in Wallingford
A new facility opened in Wallingford Saturday afternoon that treats mental health conditions with low doses of Ketamine.
Medscape6d
Ketamine-Induced Uropathy: What Urologists Need to Know
A multidisciplinary approach, including ketamine withdrawal and symptom management, is essential to mitigate long-term ...
Philippine Daily Inquirer6d
Ketamine a lifeline for severe depression patients in Singapore
Ketamine, the controlled drug best known as a horse tranquilizer or party supplement, has in the last four years become a ...